The Cipa Assay Test


Written by:

The Cipa Assay Test is one of the most common medical laboratory tests performed for cardiac health. It evaluates the health and functionality of blood vessels, and can detect a wide range of heart diseases, including cardiomyopathy and heart valve disease. It can also monitor abnormalities at the heart muscle level, such as mitral valve prolapse. FDA-approved, this test has a wide range of uses. To learn more about the test, read on to learn more about this blood test.

hERG block

The hERG block cipa assailment requires the determination of the time constant from 500ms to 15s for the onset of the hERG block. The selection of compounds should represent a broad spectrum of electrophysiological endpoints and cover a wide range of hERG blockages. These selection criteria include the degree of torsadogenic risk, action on ion channels, and non-hERG TdP.

The model is designed to simulate the action potential in human ventricular cells. It involves three steps: finding the parameters for the drug binding kinetics, computing the confidence interval, and performing the Hill Equation for the remaining six ion currents. The software CiPAORdv1.0 is written in the C programming language. Depending on the target gene, the simulation may take up to a few hours.

QT prolongation

The ability to determine if a compound will cause QT prolongation in human subjects is essential for assessing drug proarrhythmic risks. Using this assay, scientists can predict if a drug will increase the QT interval in humans and estimate the maximum free plasma concentration of a compound. A key benefit of using this assay is its low cost. It has also reduced the number of unnecessary TQT studies, which cost approximately $2 million each.

The Ca2+ transient assay has been shown to detect potential drug-induced QT prolongation and cellular arrhythmias-like early afterdepolarization in 7 of 8 high TdP-risk drugs. The results were consistent across three sites and two human hSC-CM cell lines. The assay has the potential to replace the microelectrode array and can complement the voltage-sens optical action potential recording assay.

Mitodomucous cell function

The CIPA assay for mitodomucous stellate cell function has been designed to evaluate the electrophysiological effects of a therapeutic drug in a model system that mimics the human mitodomucous stellum. Its use in predicting the electrophysiologic response of a therapeutic drug is not intended to replace clinical assessment in phase I ECG safety studies.

Comments are closed.